Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis

Yasaman Ramazani, Elena N. Levtchenko, Lambertus Van Den Heuvel, Ann Van Schepdael, Prasanta Paul, Ekaterina A. Ivanova, Anna Pastore, Trina M. Hartman, Neil P J Price

Research output: Contribution to journalArticle

Abstract

Cystinosis is a genetic disorder caused by malfunction of cystinosin and is characterized by accumulation of cystine. Cysteamine, the medication used in cystinosis, causes halitosis resulting in poor patient compliance. Halitosis is mainly caused by the formation of dimethylsulfide as the final product in the cysteamine metabolism pathway. We have synthesized carbohydrate-cysteamine thiazolidines, and hypothesized that the hydrolytic breakdown of cysteamine-thiazolidines can result in free cysteamine being released in target organs. To examine our hypothesis, we tested these analogs in vitro in patient-derived fibroblasts. Cystinotic fibroblasts were treated with different concentrations of arabinose-cysteamine, glucose-cysteamine and maltose-cysteamine. We demonstrated that the analogs break down into cysteamine extracellularly and might therefore not be fully taken up by the cells under the form of the pro-drug. Potential modifications of the analogs that enable their intracellular rather than extracellular breakdown, is necessary to pursue the potential of these analogs as pro-drugs.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalCarbohydrate Research
Volume439
DOIs
Publication statusE-pub ahead of print - Dec 18 2016

Fingerprint

Cystinosis
Thiazolidines
Cysteamine
Prodrugs
Carbohydrates
Halitosis
Therapeutics
Fibroblasts
Inborn Genetic Diseases
Arabinose
Maltose
Cystine
Patient Compliance
Metabolism

Keywords

  • Carbohydrate-cysteamine thiazolidines
  • Cysteamine
  • Cystinosis
  • Halitosis
  • Pro-drug

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Organic Chemistry

Cite this

Ramazani, Y., Levtchenko, E. N., Van Den Heuvel, L., Van Schepdael, A., Paul, P., Ivanova, E. A., ... Price, N. P. J. (2016). Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. Carbohydrate Research, 439, 9-15. https://doi.org/10.1016/j.carres.2016.12.003

Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. / Ramazani, Yasaman; Levtchenko, Elena N.; Van Den Heuvel, Lambertus; Van Schepdael, Ann; Paul, Prasanta; Ivanova, Ekaterina A.; Pastore, Anna; Hartman, Trina M.; Price, Neil P J.

In: Carbohydrate Research, Vol. 439, 18.12.2016, p. 9-15.

Research output: Contribution to journalArticle

Ramazani, Y, Levtchenko, EN, Van Den Heuvel, L, Van Schepdael, A, Paul, P, Ivanova, EA, Pastore, A, Hartman, TM & Price, NPJ 2016, 'Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis', Carbohydrate Research, vol. 439, pp. 9-15. https://doi.org/10.1016/j.carres.2016.12.003
Ramazani Y, Levtchenko EN, Van Den Heuvel L, Van Schepdael A, Paul P, Ivanova EA et al. Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. Carbohydrate Research. 2016 Dec 18;439:9-15. https://doi.org/10.1016/j.carres.2016.12.003
Ramazani, Yasaman ; Levtchenko, Elena N. ; Van Den Heuvel, Lambertus ; Van Schepdael, Ann ; Paul, Prasanta ; Ivanova, Ekaterina A. ; Pastore, Anna ; Hartman, Trina M. ; Price, Neil P J. / Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. In: Carbohydrate Research. 2016 ; Vol. 439. pp. 9-15.
@article{dca750a3c70841c398709b8c9c0343ae,
title = "Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis",
abstract = "Cystinosis is a genetic disorder caused by malfunction of cystinosin and is characterized by accumulation of cystine. Cysteamine, the medication used in cystinosis, causes halitosis resulting in poor patient compliance. Halitosis is mainly caused by the formation of dimethylsulfide as the final product in the cysteamine metabolism pathway. We have synthesized carbohydrate-cysteamine thiazolidines, and hypothesized that the hydrolytic breakdown of cysteamine-thiazolidines can result in free cysteamine being released in target organs. To examine our hypothesis, we tested these analogs in vitro in patient-derived fibroblasts. Cystinotic fibroblasts were treated with different concentrations of arabinose-cysteamine, glucose-cysteamine and maltose-cysteamine. We demonstrated that the analogs break down into cysteamine extracellularly and might therefore not be fully taken up by the cells under the form of the pro-drug. Potential modifications of the analogs that enable their intracellular rather than extracellular breakdown, is necessary to pursue the potential of these analogs as pro-drugs.",
keywords = "Carbohydrate-cysteamine thiazolidines, Cysteamine, Cystinosis, Halitosis, Pro-drug",
author = "Yasaman Ramazani and Levtchenko, {Elena N.} and {Van Den Heuvel}, Lambertus and {Van Schepdael}, Ann and Prasanta Paul and Ivanova, {Ekaterina A.} and Anna Pastore and Hartman, {Trina M.} and Price, {Neil P J}",
year = "2016",
month = "12",
day = "18",
doi = "10.1016/j.carres.2016.12.003",
language = "English",
volume = "439",
pages = "9--15",
journal = "Carbohydrate Research",
issn = "0008-6215",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis

AU - Ramazani, Yasaman

AU - Levtchenko, Elena N.

AU - Van Den Heuvel, Lambertus

AU - Van Schepdael, Ann

AU - Paul, Prasanta

AU - Ivanova, Ekaterina A.

AU - Pastore, Anna

AU - Hartman, Trina M.

AU - Price, Neil P J

PY - 2016/12/18

Y1 - 2016/12/18

N2 - Cystinosis is a genetic disorder caused by malfunction of cystinosin and is characterized by accumulation of cystine. Cysteamine, the medication used in cystinosis, causes halitosis resulting in poor patient compliance. Halitosis is mainly caused by the formation of dimethylsulfide as the final product in the cysteamine metabolism pathway. We have synthesized carbohydrate-cysteamine thiazolidines, and hypothesized that the hydrolytic breakdown of cysteamine-thiazolidines can result in free cysteamine being released in target organs. To examine our hypothesis, we tested these analogs in vitro in patient-derived fibroblasts. Cystinotic fibroblasts were treated with different concentrations of arabinose-cysteamine, glucose-cysteamine and maltose-cysteamine. We demonstrated that the analogs break down into cysteamine extracellularly and might therefore not be fully taken up by the cells under the form of the pro-drug. Potential modifications of the analogs that enable their intracellular rather than extracellular breakdown, is necessary to pursue the potential of these analogs as pro-drugs.

AB - Cystinosis is a genetic disorder caused by malfunction of cystinosin and is characterized by accumulation of cystine. Cysteamine, the medication used in cystinosis, causes halitosis resulting in poor patient compliance. Halitosis is mainly caused by the formation of dimethylsulfide as the final product in the cysteamine metabolism pathway. We have synthesized carbohydrate-cysteamine thiazolidines, and hypothesized that the hydrolytic breakdown of cysteamine-thiazolidines can result in free cysteamine being released in target organs. To examine our hypothesis, we tested these analogs in vitro in patient-derived fibroblasts. Cystinotic fibroblasts were treated with different concentrations of arabinose-cysteamine, glucose-cysteamine and maltose-cysteamine. We demonstrated that the analogs break down into cysteamine extracellularly and might therefore not be fully taken up by the cells under the form of the pro-drug. Potential modifications of the analogs that enable their intracellular rather than extracellular breakdown, is necessary to pursue the potential of these analogs as pro-drugs.

KW - Carbohydrate-cysteamine thiazolidines

KW - Cysteamine

KW - Cystinosis

KW - Halitosis

KW - Pro-drug

UR - http://www.scopus.com/inward/record.url?scp=85007245861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007245861&partnerID=8YFLogxK

U2 - 10.1016/j.carres.2016.12.003

DO - 10.1016/j.carres.2016.12.003

M3 - Article

AN - SCOPUS:85007245861

VL - 439

SP - 9

EP - 15

JO - Carbohydrate Research

JF - Carbohydrate Research

SN - 0008-6215

ER -